Verona Pharma plc - Depositary Receipt (Common Stock)
US ˙ NasdaqGM ˙ US9250501064
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityVRNA / Verona Pharma plc - Depositary Receipt (Common Stock)
InstitutionCitigroup Inc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Citigroup Inc ownership in VRNA / Verona Pharma plc - Depositary Receipt (Common Stock)

On February 13, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 0 shares of Verona Pharma plc - Depositary Receipt (Common Stock) (US:VRNA) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 10, 2025 disclosing 231,508 shares of Verona Pharma plc - Depositary Receipt (Common Stock). The current value of the position is $0 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (VRNA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F VERONA PHARMA SPONSORED ADS 925050106 0 -100.00 0
2025-11-10 2025-09-30 13F VERONA PHARMA SPONSORED ADS 925050106 231,508 226,624 4,640.13 24,704 5,258.79 0.0110
2025-08-11 2025-06-30 13F VERONA PHARMA SPONSORED ADS 925050106 4,884 3,217 192.98 462 339.05 0.0002
2025-05-12 2025-03-31 13F VERONA PHARMA SPONSORED ADS 925050106 1,667 201 13.71 106 54.41 0.0001
2025-02-12 2024-12-31 13F VERONA PHARMA SPONSORED ADS 925050106 1,466 185 14.44 68 88.89 0.0000
2024-11-12 2024-09-30 13F VERONA PHARMA SPONSORED ADS 925050106 1,281 -196 -13.27 37 71.43 0.0000
2024-08-12 2024-06-30 13F VERONA PHARMA SPONSORED ADS 925050106 1,477 1,230 497.98 21 600.00 0.0000
2024-05-10 2024-03-31 13F VERONA PHARMA SPONSORED ADS 925050106 247 -961 -79.55 4 -87.50 0.0000
2024-02-09 2023-12-31 13F VERONA PHARMA SPONSORED ADS 925050106 1,208 376 45.19 24 84.62 0.0000
2023-12-06 2023-09-30 13F/A-1 VERONA PHARMA SPONSORED ADS 925050106 832 -298 -26.37 14 -43.48 0.0000
2023-11-09 2023-09-30 13F VERONA PHARMA SPONSORED ADS 925050106 832 -298 14 0.0000
2023-08-10 2023-06-30 13F VERONA PHARMA SPONSORED ADS 925050106 1,130 407 56.29 24 64.29 0.0000
2023-05-11 2023-03-31 13F VERONA PHARMA SPONSORED ADS 925050106 723 -57 -7.31 15 -30.00 0.0000
2023-02-09 2022-12-31 13F VERONA PHARMA SPONSORED ADS 925050106 780 780 20 0.0000
2022-08-10 2022-06-30 13F VERONA PHARMA SPONSORED ADS 925050106 0 -369,008 -100.00 0 -100.00
2022-05-12 2022-03-31 13F VERONA PHARMA SPONSORED ADS 925050106 369,008 369,008 1,841 0.0011
2022-02-10 2021-12-31 13F VERONA PHARMA SPONSORED ADS 925050106 0 -495,446 -100.00 0 -100.00
2021-11-10 2021-09-30 13F VERONA PHARMA SPONSORED ADS 925050106 495,446 495,446 2,715 0.0016
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-10 2025-09-30 13F VERONA PHARMA SPONSORED ADS Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-11 2025-06-30 13F VERONA PHARMA SPONSORED ADS Call 500 47 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.